Back to AVEOView full pipeline
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
0 competitors in Metastatic Head-and-neck Squamous-cell Carcinoma
View Full LandscapeDrug Information
Target Indication
Metastatic Head-and-neck Squamous-cell Carcinoma
Clinical Trial
NCT06064877Last updated: 12/23/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Decitabine (BAML-16-001-S5)Phase 3
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Tivozanib hydrochloridePhase 3
Carcinoma, Renal Cell
TivozanibPhase 3
Renal Cell Carcinoma
tivozanib (AV-951)Phase 3
Advanced Renal Cell Carcinoma
AZD5991 (BAML-16-001-S18)Phase 3
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
